Tetrahydrofuran → 4-tert-Butoxycarbonylamino-5-(1-trityl-1H-imidazol-4-yl)-pent-2-enoic acid ethyl ester
반응식
C1(P(=[CH:20][C:21]([O:23][CH2:24][CH3:25])=[O:22])(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1.[C:26]([O:30][C:31](=[O:61])[NH:32][CH:33](C=O)[CH2:34][C:35]1[N:36]=[CH:37][N:38]([C:40]([C:53]2[CH:58]=[CH:57][CH:56]=[CH:55][CH:54]=2)([C:47]2[CH:52]=[CH:51][CH:50]=[CH:49][CH:48]=2)[C:41]2[CH:46]=[CH:45][CH:44]=[CH:43][CH:42]=2)[CH:39]=1)([CH3:29])([CH3:28])[CH3:27].[CH2:62]1COCC1>>[CH2:24]([O:23][C:21](=[O:22])[CH:20]=[CH:62][CH:33]([NH:32][C:31]([O:30][C:26]([CH3:28])([CH3:27])[CH3:29])=[O:61])[CH2:34][C:35]1[N:36]=[CH:37][N:38]([C:40]([C:47]2[CH:48]=[CH:49][CH:50]=[CH:51][CH:52]=2)([C:53]2[CH:58]=[CH:57][CH:56]=[CH:55][CH:54]=2)[C:41]2[CH:46]=[CH:45][CH:44]=[CH:43][CH:42]=2)[CH:39]=1)[CH3:25]참가 물질
실험 절차
Ethyl (triphenylphosphoranylidene)acetate (1.52 g, 4.37 mmol) and [1-formyl-2-(1-trityl-1H-imidazol-4-yl)-ethyl]-carbamic acid tert-butyl ester (2.1 g, 4.38 mmol) in THF (35 mL) were stirred overnight under argon. The solvent was removed, Et2O added and the solution filtered. The filtrate was concentrated and the residue subject to column chromatography (silica gel, 25% EA/PE, Rf 0.65 50% EA/PE) to afford the title compound (1.6 g, 67%). ESMS 552 (M+H+) Mpt . 1H NMR (300 MHz, CDCl3) δ 1.28 (3H, t, J=7.5), 1.34 (9H, s), 3.01-3.05 (2H, m), 4.19 (2H, q, J=7.05), 4.47-4.57 (1H, m), 6.01 (1H, dd, J=1.5, 15.9), 6.46 (1H, d, J=9.3), 6.86 (1H, s), 6.89 (1H, dd, J=5.1, 15.9), 7.07-7.11 (5H, m), 7.21-7.3 (2H, m), 7.4-7.44 (8H, m), 8.11 (1H, s). 13C NMR (300 MHz, CDCl3) δ 166.14, 155.87, 139.86, 135.20, 132.21, 129.49, 129.70, 129.01, 128.18, 122.33, 121.19, 79.74, 78.78, 60.76, 52.09, 30.12, 28.35, 14.32.
후처리
- customThe solvent was removed
- additionEt2O added
- filtrationthe solution filtered
- concentrationThe filtrate was concentrated
출처 및 근거
- ORD 기록
- ord-d8207051507a47278869bb26d03b066d
- 출처 데이터셋
- uspto-grants-2007_08
- 특허 번호
- US07253194B2
반응 노트
불러오는 중…